GLIDAPA TENMET 500

GLIDAPA TENMET 500 is an advanced triple fixed-dose combination medicine used in the management of Type 2 Diabetes Mellitus, designed for patients whose blood sugar remains inadequately controlled on simpler regimens, or who require a more comprehensive, multi-pathway approach to glycemic management from the outset. It brings together three complementary anti-diabetic agents, each acting through a distinct mechanism:

Dapagliflozin, an SGLT2 (Sodium-Glucose Cotransporter-2) inhibitor, works in the kidneys by blocking the reabsorption of glucose back into the bloodstream, allowing excess sugar to be excreted directly through urine. This mechanism works independently of insulin, making it valuable even as the pancreas's own insulin-producing capacity declines.

Teneligliptin, a DPP-4 (Dipeptidyl Peptidase-4) inhibitor, works by preserving the activity of incretin hormones, which help the pancreas release insulin more effectively in response to meals, while also reducing excess glucose production by the liver — with a relatively low risk of causing hypoglycemia on its own.

Metformin Hydrochloride (Extended-Release), a biguanide, reduces the amount of glucose released by the liver and improves the body's sensitivity to insulin at the cellular level. The extended-release formulation allows for steadier drug levels and generally improved gastrointestinal tolerability compared to immediate-release Metformin.

By combining these three mechanisms — glucose excretion, enhanced meal-time insulin response, and improved insulin sensitivity — GLIDAPA TENMET 500 addresses blood sugar control from multiple biological angles at once, offering a level of comprehensive glycemic management that is often difficult to achieve with single-agent or two-drug therapy, while simplifying treatment into one daily tablet.

Product Information

Why GLIDAPA TENMET 500 Is Important

Type 2 diabetes is a progressive metabolic condition, and as it advances, many patients find that earlier, simpler treatment combinations no longer keep their blood sugar adequately controlled. Consistently elevated blood glucose significantly raises the risk of long-term complications, including damage to the eyes, kidneys, nerves, and cardiovascular system, making effective and sustained control a genuine health priority rather than a secondary concern.

GLIDAPA TENMET 500 is clinically important because it:

• Offers three complementary mechanisms of action in one tablet, providing a comprehensive approach for patients with more advanced or harder-to-control diabetes
• The Dapagliflozin component works independently of insulin availability, remaining effective as pancreatic function declines over the course of the disease
• Teneligliptin's relatively low hypoglycemia risk makes it a comfortable addition for patients concerned about frequent low blood sugar episodes
• Metformin ER continues to serve as a foundational therapy, improving insulin sensitivity while reducing liver glucose output, with better gastrointestinal tolerability due to its extended-release format
• Simplifies treatment for patients who would otherwise require three separate prescriptions, supporting better long-term adherence
• SGLT2 inhibitors like Dapagliflozin have also been associated in clinical literature with modest benefits for body weight and blood pressure, relevant considerations in overall diabetes management

Because this is an advanced triple-combination medicine spanning three distinct drug classes, it requires careful physician assessment of kidney function, overall health, and cardiovascular status before initiation, along with ongoing monitoring throughout treatment.

Key Benefits

• Triple-mechanism action — combines glucose excretion, enhanced insulin response, and improved insulin sensitivity in one tablet
• Insulin-independent glucose lowering via the Dapagliflozin (SGLT2 inhibitor) component
• Low intrinsic hypoglycemia risk from the Teneligliptin component
• Reduces pill burden by combining three medicines into a single extended-release tablet
• Supports better long-term HbA1c and glycemic control, reducing risk of diabetes-related complications
• May offer additional benefits for body weight and blood pressure, relevant to overall metabolic health
• Extended-release Metformin component supports improved gastrointestinal tolerability
• Backed by WHO-GMP certified manufacturing, ensuring consistent tablet quality and dosing accuracy

Precautions

• Should be used only under medical supervision, with regular monitoring of blood glucose, HbA1c, and kidney function
• Caution advised in patients with kidney impairment, as both Dapagliflozin and Metformin require dose consideration based on kidney function
• The Dapagliflozin component increases urinary glucose excretion, which can raise the risk of genital and urinary tract infections — good hygiene and prompt reporting of symptoms is advised
• Risk of dehydration or low blood pressure, particularly in elderly patients or those on diuretics, due to the fluid-related effects of SGLT2 inhibitors
• Rare risk of diabetic ketoacidosis has been reported with SGLT2 inhibitors, even with normal or mildly elevated blood sugar — any unusual nausea, vomiting, abdominal pain, or unusual fatigue should be reported promptly
• Should be used cautiously in patients with liver disease, heart failure, or conditions predisposing to lactic acidosis (a rare but serious risk associated with Metformin)
• Temporary discontinuation may be required before procedures involving contrast dye (imaging scans) or major surgery — inform all treating doctors that this medicine is being taken
• Not recommended during pregnancy or breastfeeding unless specifically advised by a physician
• Alcohol should be avoided or limited, as it can increase the risk of lactic acidosis and dehydration-related effects
• Inform the doctor of all other medications, as several drug classes can interact with components of this combination

Side Effects

• Genital or urinary tract infections (associated with the Dapagliflozin/SGLT2 inhibitor component)
• Increased urination
• Gastrointestinal discomfort — nausea, bloating, or diarrhea (particularly with the Metformin component)
• Headache
• Nasopharyngitis (common cold-like symptoms, occasionally reported with Teneligliptin)
• Dizziness, particularly if dehydration occurs
• Metallic taste in the mouth
• Rarely: lactic acidosis (a serious condition requiring emergency care)
• Rarely: diabetic ketoacidosis, even with normal blood sugar levels — requires immediate medical attention
• Rarely: allergic skin reactions

Frequently Asked Questions

1. Where can I buy Dapagliflozin Teneligliptin Metformin Combination online?
You can buy Dapagliflozin Teneligliptin Metformin Combination through licensed online pharmacies or authorized pharmaceutical suppliers in India. Verify the manufacturer, strengths, batch number, expiry date, and packaging before purchasing.

2. What is the price of Dapagliflozin Teneligliptin Metformin Combination?
The price may vary depending on the brand, strengths, formulation, pack size, manufacturer, seller, taxes, and delivery charges. Check the current price with a licensed pharmacy or authorized supplier.

3. Can I order Dapagliflozin Teneligliptin Metformin Combination online?
Yes, this combination can be ordered online where legally available. It is generally a prescription medicine, so a valid prescription may be required. Purchase only through a licensed pharmacy or authorized supplier.

4. Is Dapagliflozin Teneligliptin Metformin Combination available from Steris Healthcare?
Availability depends on Steris Healthcare's current product range and stock status. Contact Steris Healthcare or an authorized distributor to confirm the available strengths, formulation, pack size, price, and ordering details.

5. What is Dapagliflozin Teneligliptin Metformin Combination used for?
Dapagliflozin Teneligliptin Metformin is used to help control blood glucose levels in adults with type 2 diabetes mellitus, along with a suitable diet and regular physical activity. The three medicines work through different mechanisms to improve blood sugar control.

6. What is the composition of Dapagliflozin Teneligliptin Metformin Combination?
This combination contains three active ingredients: Dapagliflozin, Teneligliptin, and Metformin Hydrochloride. The exact strength of each ingredient depends on the specific product formulation.

7. Is a prescription required?
Yes, Dapagliflozin Teneligliptin Metformin Combination is generally a prescription medicine and should be used under medical supervision. Your doctor will determine the appropriate strength and dosage based on your individual treatment needs.

8. How should Dapagliflozin Teneligliptin Metformin Combination be taken?
Take the combination exactly as prescribed by your doctor. It is generally taken orally and may be taken with food depending on the formulation. Swallow the tablet with water and do not change the dose or stop treatment without medical advice.

9. What should I know before buying Dapagliflozin Teneligliptin Metformin Combination?
Before buying, verify the exact strengths, formulation, manufacturer, batch number, expiry date, packaging, and storage instructions. Inform your doctor about kidney or liver problems, dehydration, low blood pressure, urinary or genital infections, pancreatitis, pregnancy or breastfeeding, and all medicines or supplements you take.

10. How can I order Dapagliflozin Teneligliptin Metformin Combination online?
To order this combination online, choose a licensed pharmacy or authorized supplier, select the prescribed strength and pack size, provide a valid prescription if required, verify the product and expiry details, and complete the purchase.